Goldman Sachs raised the firm’s price target on Oscar Health to $16 from $8 and keeps a Neutral rating on the shares after its Q4 results. The company’s FY24 adjusted EBITDA outlook exceeded estimates, helped by geographical expansion, high retention, and strong SEP additions, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OSCR:
